ARA-290 / Cibinetide Peptide Intelligence Monograph | FIME

Neuropathy • Tissue Protection • Inflammation • Small-Fiber Nerve Biology • Repair Signaling

ARA-290, later developed as cibinetide, represents an unusual chapter in peptide science: an erythropoietin-derived molecule engineered to explore tissue-protective and repair signaling without the red-blood-cell-stimulating activity of EPO.

And unlike many experimental peptides, cibinetide made the important leap from laboratory research into controlled human clinical trials.

The FIME ARA-290 / Cibinetide Peptide Intelligence Monograph examines its development, proposed Innate Repair Receptor biology, anti-inflammatory and tissue-protective research, and human investigations involving small-fiber neuropathy, neuropathic symptoms, and corneal nerve structure.

The monograph also examines what those findings do—and do not—establish about nerve regeneration, pain, metabolic disease, tissue repair, and broader regenerative claims, while addressing the crucial distinction between pharmaceutical-development cibinetide and products sold today as research-market ARA-290.

ARA-290 became more than a promising mechanism. It became an experimental medicine. Whether it becomes established medicine remains the unanswered question.

Real human trials. Promising biological signals. Clinical certainty still to be earned.

Version 1.0 Final
Founder’s Institute of Medicine & Education

For professional education and scientific review. Not individualized medical advice, prescribing guidance, neuropathy treatment, regenerative-medicine guidance, or a treatment protocol.